SCHEMBL343309

SCHEMBL343309

CC(N)(Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
KDM4E B2RXH2 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
ALDH1A1 P00352 3/20 0.54
HPGD P15428 1/20 0.54
LMNA P02545 3/20 0.54
TSHR P16473 2/20 0.54
BLM P54132 2/20 0.54
APAF1 O14727 1/20 0.54
POLB P06746 1/20 0.54
RECQL P46063 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MPO P05164 1/20 0.54
PMP22 Q01453 1/20 0.54
HIF1A Q16665 1/20 0.54
SLC6A2 P23975 1/20 0.51
FNTA P49354 1/20 0.51
FNTB P49356 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162554 1.00 MAPT (0.54) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL30135703 1.00 MAPT (0.54) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL29434606 1.00 MAPT (0.54) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL29355137 1.00 MAPT (0.54) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL200589 1.00 MAPT (0.54) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL29588649 1.00 MAPT (0.54) MAPTMEN1KMT2AKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL8995746 0.99 MAPT (0.52) MAPTMEN1KMT2AKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL6112940 0.99 MAPT (0.52) MAPTMEN1KMT2AKDM4ESMN1; SMN2
Metyrosine SCHEMBL2722717 0.90 BLM (0.62) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL10077124 0.88 MEN1 (0.52) MAPTMEN1KMT2AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. 2025-09-04 US claimed
CN-120157771-A Incretin polypeptide analogue and application thereof 北京诺尼瑞生物科技有限责任公司 2025-06-17 CN claimed
WO-2024206577-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-10-03 WO claimed
US-20240226225-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2024-07-11 US claimed
EP-4392440-A2 COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS River 2 Renal Corp. (US) 2024-07-03 EP claimed
US-20240209053-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2024-06-27 US claimed
US-20240197896-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY FELDAN BIO INC. (CA) 2024-06-20 US claimed
CN-117813313-A Binding hepcidin mimetics 领导医疗有限公司 2024-04-02 CN claimed
CN-117750978-A Synthetic peptide shuttle bioconjugates for intracellular cargo delivery 费尔丹生物公司 2024-03-22 CN claimed
CN-117730089-A Binding hepcidin mimetics 领导医疗有限公司 2024-03-19 CN claimed
WO-2012120532-A2 CYCLIC SHORT CHAIN PEPTIDES CADILA HEALTHCARE LIMITED (IN) 2012-09-13 WO claimed
US-8062870-B2 Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs XENOPORT, INC. (US) 2011-11-22 US claimed
WO-2011100295-A2 ALPHA-METHYL-TRYPTOPHAN AS AN INHIBITOR OF INDOLEAMINE DIOXYGENASE MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) 2011-08-18 WO claimed
CN-101155549-A Functionalized magnetic nanoparticles and methods of use thereof UNIV CALIFORNIA (US) 2008-04-02 CN claimed
US-20080028488-A1 USE OF TRYPTOPHAN INDOLE AND ANTHRANILATE ANALOGS AS PLANT TRANSFORMATION SELECTION AGENTS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2008-01-31 US claimed
EP-0546123-A4 1994-04-27 EP claimed
EP-0546123-A1 ALPHA-SUBSTITUTED TRYPTOPHANE DIPEPTOID DERIVATIVES WARNER-LAMBERT COMPANY (US) 1993-06-16 EP claimed
WO-1992004322-A1 ALPHA-SUBSTITUTED TRYPTOPHANE DIPEPTOID DERIVATIVES WARNER-LAMBERT COMPANY (US) 1992-03-19 WO claimed
EP-0036713-B1 ANGIOTENSIN CONVERTING ENZYME INHIBITORS UNIVERSITY OF MIAMI (US) 1984-01-18 EP claimed
US-3988341-A Esterification process MERCK & CO., INC. (US) 1976-10-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240197896-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY SCAMP2, SLC7A1, NUMA1 MAPT 2658/4885MEN1 322/4885KMT2A 4507/4885
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, VIP, HDGF MAPT 4701/4885MEN1 161/4885KMT2A 3788/4885
US-20240226225-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, SLC40A1, FTH1 MAPT 3675/4885MEN1 225/4885KMT2A 2322/4885
US-20240209053-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, SLC40A1, FTH1 MAPT 3901/4885MEN1 188/4885KMT2A 3289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.